Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137)
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)
- Status
- COMPLETED
- Phase
- PHASE2
Study Comparing Pembrolizumab With Dual MAPK Pathway Inhibition Plus Pembrolizumab in Melanoma Patients
- Status
- UNKNOWN
- Phase
- PHASE2
Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173)
- Status
- COMPLETED
- Phase
- PHASE1
Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- Status
- RECRUITING
- Phase
- PHASE2
Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma
- Status
- COMPLETED
- Phase
- PHASE1
Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma
- Status
- COMPLETED
- Phase
- PHASE1
Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122)
- Status
- COMPLETED
- Phase
- PHASE3
Pembrolizumab + Radiation for Locally Adv SCC of the Head and Neck (SCCHN) Not Eligible Cisplatin
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Study of Pembrolizumab for Patients With Thymic Epithelial Tumor
- Status
- COMPLETED
- Phase
- PHASE2
Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- EARLY_PHASE1
Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer
- Status
- RECRUITING
- Phase
- PHASE1
A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients
- Status
- COMPLETED
- Phase
- PHASE2
Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2